Alpha Tau Medical (DRTS) Common Equity (2020 - 2026)

Alpha Tau Medical (DRTS) has 7 years of Common Equity data on file, last reported at $69.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 23.13% year-over-year to $69.4 million; the trailing twelve-month figure through Mar 2026 stood at $69.4 million (up 23.13% YoY), and the FY2025 full-year result was $77.1 million, up 23.03% from the prior year.
• Common Equity fell to $69.4 million in Q1 2026, from $77.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $108.3 million in Q2 2022 to a low of $56.3 million in Q1 2025.
• A 5-year average of $84.3 million and a median of $84.5 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 403.81% in 2022 and fell 28.76% in 2025, its largest moves.
• Tracing DRTS's Common Equity over 5 years: stood at $105.7 million in 2022, then retreated by 20.05% to $84.5 million in 2023, then declined by 25.82% to $62.7 million in 2024, then gained by 23.03% to $77.1 million in 2025, then fell by 10.05% to $69.4 million in 2026.
• Business Quant data shows DRTS's Common Equity at $69.4 million in Q1 2026, $77.1 million in Q4 2025, and $77.6 million in Q3 2025.